TICKERNOMICS Sign up
Last Update: 2024-12-27 15:23:09
Apellis Pharmaceuticals Inc. ( APLS ) https://www.apellis.com
32.95USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-47.55%
APLS
SPY
32.66%
-30.33%
APLS
SPY
108.59%
APLS
14.67%
SPY
302.52%
APLS
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
4128.48
3749.82
1.06
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-16.51
5.94
17.41
-5.40
0.00
-20.33
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-26.78
81.00
-25.44
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.6256
-32.75
-32.83
1.17
Other Earnings and Cash Flow Stats:
Apellis Pharmaceuticals Inc. ( APLS ) Net Income TTM ($MM) is -250.10
Apellis Pharmaceuticals Inc. ( APLS ) Operating Income TTM ($MM) is -223.33
Apellis Pharmaceuticals Inc. ( APLS ) Owners' Earnings Annual ($MM) is 0.00
Apellis Pharmaceuticals Inc. ( APLS ) Current Price to Owners' Earnings ratio is 0.00
Apellis Pharmaceuticals Inc. ( APLS ) EBITDA TTM ($MM) is -221.66
Apellis Pharmaceuticals Inc. ( APLS ) EBITDA Margin is -25.44%
Capital Allocation:
Apellis Pharmaceuticals Inc. ( APLS ) has paid 0.00 dividends per share and bought back -3.612 million shares in the past 12 months
Apellis Pharmaceuticals Inc. ( APLS ) has reduced its debt by 97.112 million USD in the last 12 months
Capital Structure:
Apellis Pharmaceuticals Inc. ( APLS ) Interest-bearing Debt ($MM) as of last quarter is 18
Apellis Pharmaceuticals Inc. ( APLS ) Annual Working Capital Investments ($MM) are -102
Apellis Pharmaceuticals Inc. ( APLS ) Book Value ($MM) as of last quarter is 237
Apellis Pharmaceuticals Inc. ( APLS ) Debt/Capital as of last quarter is 7%
Other Balance Sheet Stats:
Apellis Pharmaceuticals Inc. ( APLS ) has 396 million in cash on hand as of last quarter
Apellis Pharmaceuticals Inc. ( APLS ) has 191 million of liabilities due within 12 months, and long term debt 457 as of last quarter
Apellis Pharmaceuticals Inc. ( APLS ) has 123 common shares outstanding as of last quarter
Apellis Pharmaceuticals Inc. ( APLS ) has 0 million USD of preferred stock value
Academic Scores:
Apellis Pharmaceuticals Inc. ( APLS ) Altman Z-Score is 0.05 as of last quarter
Apellis Pharmaceuticals Inc. ( APLS ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Apellis Pharmaceuticals Inc. ( APLS ) largest shareholder is owning shares at 0.00 ($MM) value
Watson David O.(an insider) Sold 5000 shares of Apellis Pharmaceuticals Inc. ( APLS ) for the amount of $171175.00 on 2024-12-11
13.98% of Apellis Pharmaceuticals Inc. ( APLS ) is held by insiders, and 95.29% is held by institutions
Apellis Pharmaceuticals Inc. ( APLS ) went public on 2017-11-09
Other Apellis Pharmaceuticals Inc. ( APLS ) financial metrics:
FCF:-205.67
Unlevered Free Cash Flow:-645.14
EPS:-1.85
Operating Margin:-26.78
Gross Profit Margin:81.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-96.90
Beta:1.17
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Apellis Pharmaceuticals Inc. ( APLS ) :
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.